The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
Open accessAbstract
Alopecia areata (AA) is a common autoimmune disease, with a lifetime risk of ~2%. In AA, the immune systems targets the hair follicle, resulting in clinical hair loss. AA prognosis is unpredictable, and currently there is no definitive treatment. Our previous whole genome expression studies identified active immune circuits in AA lesions, including common γ-chain cytokine and IFN pathways. Since these pathways are mediated through JAK kinases, we prioritized clinical exploration of small molecule JAK inhibitors. In preclinical trials in mice, tofacitinib successfully prevented AA development and reversed established disease. In our tofacitinib trial in 12 patients with moderate to severe AA, 11 patients completed a full course of treatment with minimal adverse events. Following limited response to the initial dose (5mg BID), the dose was escalated (10mg BID) for nonresponding subjects. Eight of 12 patients demonstrated ≥50% hair regrowth while 3 patients demonstrated <50% hair regrowth as measured by SALT score. One patient demonstrated no regrowth. Gene expression profiles and Alopecia Areata Disease Activity Index (ALADIN) scores correlated with clinical response. Our open label studies of ruxolitinib and tofacitinib have shown dramatic clinical responses in moderate-to-severe AA, providing strong rationale for larger clinical trials using JAK inhibitors in AA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Schwartz, D. M., Bonelli, M., Gadina, M., & O'Shea, J. J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.167 · Cited by 648
Chen, J. C., Alvarez, M. J., Talos, F., Dhruv, H., Rieckhof, G. E., Iyer, A., Diefes, K. L., Aldape, K., Berens, M., Shen, M. M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.021 · Cited by 188
Self-citation
Cited by
Two Phase 3 Trials of Baricitinib for Alopecia Areata
King, B., Ohyama, M., Kwon, O., Zlotogorski, A., Ko, J., Mesinkovska, N. A., Hordinsky, M., Dutronc, Y., Wu, W.-S., McCollam, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2110343 · Cited by 506
Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management
Zhou, C., Li, X., Wang, C., & Zhang, J. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08883-0 · Cited by 393
Emerging Topical and Systemic JAK Inhibitors in Dermatology
Solimani, F., Meier, K., & Ghoreschi, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02847 · Cited by 308
JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
Fragoulis, G. E., McInnes, I. B., & Siebert, S. (2019) · Rheumatology · doi:10.1093/rheumatology/key276 · Cited by 296
Unmet medical needs in chronic, non-communicable inflammatory skin diseases
Ujiie, H., Rosmarin, D., Schön, M. P., Ständer, S., Boch, K., Metz, M., Maurer, M., Thaci, D., Schmidt, E., Cole, C., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.875492 · Cited by 158
“Blockade of JAK1/3 and JAK 1/2 by the oral selective inhibitors, tofacitinib, and ruxolitinib, respectively, was shown to be effective in inducing regrowth of hair in AAP and AT/AU patients with active and chronic disease (159, 160).”
Background
Metadata
- Authors
- Jabbari, A., Sansaricq, F., Cerise, J., Chen, J. C., Bitterman, A., Ulerio, G., Borbon, J., Clynes, R., Christiano, A. M., & Mackay-Wiggan, J.
- Venue
- Journal of Investigative Dermatology
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 138
- Issue
- 7
- Pages
- 1539-1545
- ISSN
- 0022-202X (ISSN-L)
- OpenAlex
- W2785664987
- Cited by
- 188
- References
- 2
- FWCI
- 23.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis. https://app.cochat.ai/papers/10.1016/j.jid.2018.01.032
- The paper
- Jabbari, A., Sansaricq, F., Cerise, J., Chen, J. C., Bitterman, A., Ulerio, G., Borbon, J., Clynes, R., Christiano, A. M., & Mackay-Wiggan, J. (2018). An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2018.01.032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.